Probiotic composition and application thereof in preparation of medicines for treating co-disease constipation and depression

Abstract

The invention provides a probiotic composition and an application thereof in preparation of medicines for treating co-disease constipation and depression. The composition comprises bifidobacterium animalis subsp. Lactis U9, lactobacillus paracasei L55, lactobacillus rhamnosus LL23, bifidobacterium adolescentis BQ23 and lactobacillus acidophilus RA15. According to the invention, a random double-blind test is carried out to carry out probiotic intervention on depression patients. According to the invention, 63 depression patients are recruited in total, and 31 of the patients suffer from constipation. The result shows that after 8 weeks of intervention, the HAMD score of the probiotic group of the depression crowd with co-disease constipation is reduced to 14.2 + / -8.0, which is significantly lower than that of a placebo group (22.9 + / -9.9, P is less than 0.05), and the HAMD score of the probiotic group of the depression crowd without constipation has no significant difference from that of the placebo group. The probiotic composition disclosed by the invention can be used for effectively relieving the depressive symptoms of depressive people with co-disease constipation.

Description

technical field [0001] The invention belongs to the technical field of probiotics, and in particular relates to a probiotic composition and its application in preparing medicines for comorbid constipation and depression. Background technique [0002] Depression is a common and dangerous mental illness. According to the report of the World Health Organization, patients with depression accounted for about 4.4% of the total population in 2015, and the total number of patients was as high as 322 million. Although both depression and constipation can occur independently, studies have shown a high rate of comorbidity between the two. It is reported that 57.7% of depressed patients are accompanied by constipation symptoms, and their probability of suffering from constipation is 1.8 times that of ordinary people. Patients with gastrointestinal disorders were also more likely to suffer from depression, with a prevalence as high as 33 percent among chronic constipation patients. It...

AI Technical Summary

Problems solved by technology

[0004] The purpose of the present invention is to overcome the problem that the probiotics in the prior art have large differences in the effect of improving the depressive symptoms of patients, and provide a probiotic composition and its application in the preparation of comorbid constipation and depression drugs. Bacterial composition can effectively relieve depressive symptoms in depressed people with comorbid constipation

Images